Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke

Fang, 2001, Trend of stroke hospitalization, United States, 1988–1997, Stroke, 32, 2221, 10.1161/hs1001.096193

Botte, 1988, Spasticity and contracture. Physiologic aspects of formation, Clin Orthop, Aug, 7

Akeson, 1973, The connective tissue response to immobility, Clin Orthop, Jun, 356, 10.1097/00003086-197306000-00039

Kottke, 1966, The rationale for prolonged stretching for correction of shortening of connective tissue, Arch Phys Med Rehabil, 47, 345

Mayer, 1997, Common patterns of clinical motor dysfunction, Muscle Nerve Suppl, 6, S21, 10.1002/(SICI)1097-4598(1997)6+<21::AID-MUS4>3.0.CO;2-L

Lance, 1980, Symposium synopsis, 485

Barnes, 1998, Management of spasticity, Age Aging, 27, 239, 10.1093/ageing/27.2.239

Bhakta, 1996, Use of botulinum toxin in stroke patients with severe upper limb spasticity, J Neurol Neurosurg Psychiatry, 61, 30, 10.1136/jnnp.61.1.30

O’Brien, 1996, Spasticity after stroke, Drugs Aging, 9, 332, 10.2165/00002512-199609050-00004

Little, 1988, Spasticity and associated abnormalities of muscle tone, 565

Losseff, 1995, The medical management of increased tone, Physiotherapy, 81, 480, 10.1016/S0031-9406(05)66744-2

Garland, 1984, Percutaneous phenol blocks to motor points of spastic forearm muscles in head-injured adults, Arch Phys Med Rehabil, 65, 243

Yablon, 2001, Botulinum neurotoxin intramuscular chemodenervation. Role in the management of spastic hypertonia and related motor disorders, Phys Med Rehabil Clin North Am, 12, 833, 10.1016/S1047-9651(18)30035-4

Dolly, 2003, Synaptic transmission, Headache, 43, 16, 10.1046/j.1526-4610.43.7s.4.x

Angaut-Petit, 1990, Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin, Neuroscience, 37, 799, 10.1016/0306-4522(90)90109-H

De Paiva, 1999, Functional repair of motor endplates after botulinum neurotoxin type A poisoning, Proc Natl Acad Sci U S A, 96, 3200, 10.1073/pnas.96.6.3200

Simpson, 1996, Botulinum toxin type A in the treatment of upper extremity spasticity, Neurology, 46, 1306, 10.1212/WNL.46.5.1306

Wissel, 1999, Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy, Neuropediatrics, 30, 120, 10.1055/s-2007-973475

Burbaud, 1996, A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients, J Neurol Neurosurg Psychiatry, 61, 265, 10.1136/jnnp.61.3.265

Dunne, 1995, Treatment of chronic limb spasticity with botulinum toxin A, J Neurol Neurosurg Psychiatry, 58, 232, 10.1136/jnnp.58.2.232

Hesse, 1994, Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients, J Neurol Neurosurg Psychiatry, 57, 1321, 10.1136/jnnp.57.11.1321

Grazko, 1995, Botulinum toxin A for spasticity, muscle spasms, and rigidity, Neurology, 45, 712, 10.1212/WNL.45.4.712

Brashear, 2002, Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke, N Engl J Med, 347, 395, 10.1056/NEJMoa011892

Ashworth, 1964, Preliminary trial of carisoprodol in multiple sclerosis, Practitioner, 192, 540

Brashear, 2002, Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity, Arch Phys Med Rehabil, 83, 1349, 10.1053/apmr.2002.35474

Hobart, 2001, Evidence-based measurement, Neurology, 57, 639, 10.1212/WNL.57.4.639

Ware, 1993

Brazier, 1992, Validating the SF-36 health survey questionnaire, BMJ, 305, 160, 10.1136/bmj.305.6846.160

Garratt, 1993, The SF-36 health survey questionnaire, BMJ, 306, 1440, 10.1136/bmj.306.6890.1440

Jenkinson, 1994, Criterion validity and reliability of the SF-36 in a population sample, Qual Life Res, 3, 7, 10.1007/BF00647843

McHorney, 1993, The MOS 36-Item Short Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs, Med Care, 31, 247, 10.1097/00005650-199303000-00006

Hawley, 1999, Use of the functional assessment measure (FIM+FAM) in head injury rehabilitation, J Neurol Neurosurg Psychiatry, 67, 749, 10.1136/jnnp.67.6.749

Childers, 1998, Evaluating motor end-plate-targeted injections of botulinum toxin type A in a canine model, Muscle Nerve, 21, 653, 10.1002/(SICI)1097-4598(199805)21:5<653::AID-MUS15>3.0.CO;2-W

Bhakta, 1996, Use of botulinum toxin in stroke patients with severe upper limb spasticity, J Neurol Neurosurg Psychiatry, 61, 30, 10.1136/jnnp.61.1.30

Dunne, 1995, Treatment of chronic limb spasticity with botulinum toxin A, J Neurol Neurosurg Psychiatry, 58, 232, 10.1136/jnnp.58.2.232

Hesse, 1994, Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients, J Neurol Neurosurg Psychiatry, 57, 1321, 10.1136/jnnp.57.11.1321

Pierson, 1996, Botulinum toxin A in the treatment of spasticity, Arch Phys Med Rehabil, 77, 717, 10.1016/S0003-9993(96)90015-5

Shaari, 1993, Quantifying how location and dose of botulinum toxin injections affect muscle paralysis, Muscle Nerve, 16, 964, 10.1002/mus.880160913